Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06658002
PHASE3

Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A

Sponsor: University of California, San Francisco

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2025-09-01

Completion Date

2027-09-01

Last Updated

2025-10-06

Healthy Volunteers

No

Interventions

DRUG

Cyclosporine A

Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.

OTHER

Placebo Comparator: Placebo

Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.

Locations (2)

University of California, San Farncisco

San Francisco, California, United States

Aravind Eye Institute

Pondicherry, Tamil Nadu, India